Phase II evaluation of mitozolomide in ovarian cancer.
Harding
M
M
Department of Medical Oncology, Gartnavel General Hospital, Glasgow, UK.
Northcott
D
D
Smyth
J
J
Stuart
N S
NS
Green
J A
JA
Newlands
E
E
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; C040369:mitozolomide